+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report by Route of Administration (Topical, Transdermal, Others), Product, Service, End-use, Country, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 140 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024547
Description Jump to:
The global semi-solid Dosage CDMO market is expected to reach USD 67.4 billion by 2030, and anticipated to grow at a CAGR of 11.80% from 2024 to 2030 . The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights

  • Based on product, topical segment dominated in the market with a share of 88.48% in 2023. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
  • Based on rout of administration, creams and lotions dominated the market in 2023. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment’s growth
  • Based on service, the contract manufacturing segment accounted for the largest revenue share in 2023. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
  • Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2023 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
  • North America dominated the market with a share of 41.12% in 2023. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Semi-Solid Dosage CDMO market include:

  • The Lubrizol Corporation
  • Cambrex Corporation
  • Contract Pharmaceuticals Limited.
  • Bora Pharmaceutical
  • Ascendia Pharmaceuticals
  • Pierre Fabre group
  • Piramal Pharma Solutions
  • DPT Laboratories, LTD
  • LGM Pharma
  • Pace Analytical Life Sciences, LLC


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Route of Administration
1.2.2. Product
1.2.3. Service
1.2.4. End Use
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Semi-Solid Dosage CDMO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis
4.1. Semi-Solid Dosage CDMO Market, By Route of Administration: Segment Dashboard
4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis
4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
4.3.1. Topical
4.3.1.1. Topical Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
4.3.2. Transdermal
4.3.2.1. Transdermal Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
4.3.3. Others
4.3.3.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis
5.1. Semi-Solid Dosage CDMO Market, By Product: Segment Dashboard
5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis
5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
5.3.1. Ointments
5.3.1.1. Ointments Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
5.3.2. Creams and Lotions
5.3.2.1. Creams and Lotions Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
5.3.3. Pastes
5.3.3.1. Pastes Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
5.3.4. Gels
5.3.4.1. Gels Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
5.3.5. Others
5.3.5.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis
6.1. Semi-Solid Dosage CDMO Market, By Service: Segment Dashboard
6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis
6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030
6.3.1. Contract Development
6.3.1.1. Contract Development Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
6.3.2. Contract Manufacturing
6.3.2.1. Contract Manufacturing Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis
7.1. Semi-Solid Dosage CDMO Market, By End Use: Segment Dashboard
7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis
7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
7.3.1. Pharmaceutical Companies
7.3.1.1. Pharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
7.3.2. Biopharmaceutical Companies
7.3.2.1. Biopharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
7.3.3. Others
7.3.3.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. North America
8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Canada Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. Mexico Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5. Europe
8.5.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. UK Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Germany Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. France Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Italy Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Spain Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.7. Sweden
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Sweden Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Framework
8.5.8.4. Denmark Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Competitive Scenario
8.5.9.3. Regulatory Framework
8.5.9.4. Norway Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.6. Asia Pacific
8.6.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Japan Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. China Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. India Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.6.5. Thailand
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Thailand Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. South Korea Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.6.7. Australia
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Australia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.7. Latin America
8.7.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Brazil Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Argentina Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.8. MEA
8.8.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. South Africa Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Saudi Arabia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Framework
8.8.4.4. UAE Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Competitive Scenario
8.8.5.3. Regulatory Framework
8.8.5.4. Kuwait Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.1.1. Innovators
9.1.2. Market Leaders
9.1.3. Emerging Players
9.2. Company Market Share/Position Analysis, 2023
9.3. Company Profiles
9.3.1. The Lubrizol Corporation
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Cambrex Corporation
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Contract Pharmaceuticals Limited.
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Bora Pharmaceutical
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Ascendia Pharmaceuticals
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Pierre Fabre group
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Piramal Pharma Solutions
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. DPT Laboratories, LTD
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. LGM Pharma
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Pace Analytical Life Sciences, LLC.
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
List of Tables
Table 1. List of Tables
Table 2. List of Secondary Sources
Table 3. List of Abbreviations
Table 4. Global Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 5. Global Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 6. Global Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 7. Global Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 8. Global Semi-Solid Dosage CDMO, by Region, 2018 - 2030 (USD Million)
Table 9. North America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
Table 10. North America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 11. North America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 12. North America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 13. North America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 14. U.S. Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 15. U.S. Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 16. U.S. Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 17. U.S. Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 18. Canada Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 19. Canada Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 20. Canada Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 21. Canada Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 22. Mexico Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 23. Mexico Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 24. Mexico Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 25. Mexico Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 26. Europe Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
Table 27. Europe Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 28. Europe Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 29. Europe Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 30. Europe Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 31. UK Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 32. UK Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 33. UK Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 34. UK Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 35. Germany Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 36. Germany Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 37. Germany Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 38. Germany Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 39. France Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 40. France Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 41. France Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 42. France Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 43. Italy Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 44. Italy Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 45. Italy Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 46. Italy Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 47. Spain Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 48. Spain Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 49. Spain Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 50. Spain Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 51. Denmark Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 52. Denmark Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 53. Denmark Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 54. Denmark Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 55. Sweden Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 56. Sweden Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 57. Sweden Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 58. Sweden Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 59. Norway Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 60. Norway Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 61. Norway Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 62. Norway Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 63. Asia Pacific Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
Table 64. Asia Pacific Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 65. Asia Pacific Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 66. Asia Pacific Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 67. Asia Pacific Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 68. Japan Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 69. Japan Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 70. Japan Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 71. Japan Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 72. China Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 73. China Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 74. China Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 75. China Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 76. India Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 77. India Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 78. India Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 79. India Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 80. Thailand Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 81. Thailand Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 82. Thailand Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 83. Thailand Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 84. South Korea Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 85. South Korea Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 86. South Korea Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 87. South Korea Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 88. Australia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 89. Australia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 90. Australia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 91. Australia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 92. Latin America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
Table 93. Latin America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 94. Latin America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 95. Latin America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 96. Latin America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 97. Brazil Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 98. Brazil Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 99. Brazil Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 100. Brazil Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 101. Argentina Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 102. Argentina Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 103. Argentina Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 104. Argentina Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 105. Middle East & Africa Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
Table 106. Middle East & Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 107. Middle East & Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 108. Middle East & Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 109. Middle East & Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 110. South Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 111. South Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 112. South Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 113. South Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 114. Saudi Arabia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 115. Saudi Arabia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 116. Saudi Arabia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 117. Saudi Arabia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 118. UAE Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 119. UAE Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 120. UAE Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 121. UAE Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
Table 122. Kuwait Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
Table 123. Kuwait Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
Table 124. Kuwait Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
Table 125. Kuwait Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Semi-Solid Dosage CDMO Market revenue, 2018-2030 (USD Million)
Fig. 10 Semi-Solid Dosage CDMO Market snapshot
Fig. 11 Semi-Solid Dosage CDMO Market driver impact
Fig. 12 Semi-Solid Dosage CDMO Market restraint impact
Fig. 13 Semi-Solid Dosage CDMO sector Route of administration takeaways (USD Million)
Fig. 14 Semi-Solid Dosage CDMO Market: Route of administration movement analysis
Fig. 15 Topical market, 2018 - 2030 (USD Million)
Fig. 16 Transdermal market, 2018 - 2030 (USD Million)
Fig. 17 Others market, 2018 - 2030 (USD Million)
Fig. 18 Semi-Solid Dosage CDMO sector Product takeaways (USD Million)
Fig. 19 Semi-Solid Dosage CDMO Market: Product movement analysis
Fig. 20 Ointments market, 2018 - 2030 (USD Million)
Fig. 21 Creams and Lotions market, 2018 - 2030 (USD Million)
Fig. 22 Pastes market, 2018 - 2030 (USD Million)
Fig. 23 Gels market, 2018 - 2030 (USD Million)
Fig. 24 Others market, 2018 - 2030 (USD Million)
Fig. 25 Semi-Solid Dosage CDMO sector Service takeaways (USD Million)
Fig. 26 Semi-Solid Dosage CDMO Market: Service movement analysis
Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
Fig. 28 Contract Manufacturing market, 2018 - 2030 (USD Million)
Fig. 29 Semi-Solid Dosage CDMO sector End Use takeaways (USD Million)
Fig. 30 Semi-Solid Dosage CDMO Market: End Use movement analysis
Fig. 31 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
Fig. 32 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
Fig. 33 Others market, 2018 - 2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 Regional outlook, 2023 & 2030
Fig. 36 North America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 37 U.S. Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 38 Canada Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 39 Mexico Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 40 Europe Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 41 UK Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 42 Germany Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 43 France Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 44 Italy Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 45 Spain companion animal Health market, 2018 - 2030 (USD Million)
Fig. 46 Sweden Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 47 Denmark Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 48 Norway Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 49 Asia Pacific Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 50 Japan Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 51 China Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 52 India Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 53 Thailand Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 54 South Korea Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 55 Australia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 56 Latin America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 57 Brazil Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 58 Argentina Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 59 Middle East & Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 60 South Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 61 Saudi Arabia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 62 UAE Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 63 Kuwait Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
Fig. 64 Market participant categorization

Companies Mentioned

  • The Lubrizol Corporation
  • Cambrex Corporation
  • Contract Pharmaceuticals Limited.
  • Bora Pharmaceutical
  • Ascendia Pharmaceuticals
  • Pierre Fabre group
  • Piramal Pharma Solutions
  • DPT Laboratories, LTD
  • LGM Pharma
  • Pace Analytical Life Sciences, LLC

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages140
PublishedOctober 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 31.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 67.4 Billion
Compound Annual Growth Rate11.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Semi-Solid CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Semi-Solid CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Upstream, Downstream), By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Upstream, Downstream), By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 317 Pages
  • Global
From
Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030 - Product Image

Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030

  • Report
  • 342 Pages
  • Global
From
Nutraceuticals CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Nutraceuticals CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.